C
Chrystal U. Louis
Researcher at Baylor College of Medicine
Publications - 39
Citations - 4801
Chrystal U. Louis is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Antigen & Cytotoxic T cell. The author has an hindex of 18, co-authored 37 publications receiving 3840 citations. Previous affiliations of Chrystal U. Louis include Houston Methodist Hospital & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
A single institution experience with pediatric nasopharyngeal carcinoma: High incidence of toxicity associated with platinum-based chemotherapy plus IMRT
Chrystal U. Louis,Arnold dela Cruz Paulino,Stephen Gottschalk,Allison A. Bertuch,Murali Chintagumpala,Helen E. Heslop,Heidi V. Russell +6 more
TL;DR: The authors did not observe a significant decrease in long-term toxicities with IMRT plus chemotherapy in a small cohort of pediatric NPC patients.
Journal Article
Advances in chimeric antigen receptor immunotherapy for neuroblastoma.
Andras Heczey,Chrystal U. Louis +1 more
TL;DR: Several approaches may further enhance anti-tumor activity and persistence of CAR modified cells, and if these can be safely translated into the clinic, CAR-based immunotherapy could become a viable adjunct or potential alternative to conventional treatment options for patients with NBL.
Journal ArticleDOI
New aspects of neuroblastoma treatment: ASPHO 2011 symposium review
TL;DR: In this article, a new international risk classification system for risk stratification and for treatment based on novel tumor targets and including immunotherapy are employed in attempts to improve the outcomes of children with neuroblastoma.
Journal ArticleDOI
The optimal timing of surgical resection in high-risk neuroblastoma
Yesenia Rojas,Sergio Jaramillo,Karen M. Lyons,Nadia Mahmood,Meng-Fen Wu,Hao Liu,Sanjeev A. Vasudevan,R. Paul Guillerman,Chrystal U. Louis,Heidi V. Russell,Jed G. Nuchtern,Eugene S. Kim,Eugene S. Kim +12 more
TL;DR: HRNB patients who received 4cycles of chemotherapy prior to surgical resection have a superior OS than patients who receive 2.5cycles, and further studies are warranted to elucidate these differences.
Journal ArticleDOI
Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell Immunotherapy
Mamta Kalra,Ulrike Gerdemann,Ulrike Gerdemann,Jessica D. Luu,Jessica D. Luu,Minthran C. Ngo,Minthran C. Ngo,Ann M. Leen,Chrystal U. Louis,Chrystal U. Louis,Cliona M. Rooney,Stephen Gottschalk +11 more
TL;DR: Targeting BARF1, in addition to EBNA1, LMP1 and LMP2, has the potential to improve the efficacy of current T-cell immunotherapy approaches for these malignancies.